294 related articles for article (PubMed ID: 30043641)
1. Cancer-targeted delivery systems based on peptides.
Chatzisideri T; Leonidis G; Sarli V
Future Med Chem; 2018 Sep; 10(18):2201-2226. PubMed ID: 30043641
[TBL] [Abstract][Full Text] [Related]
2. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy.
Nagy A; Schally AV
Curr Pharm Des; 2005; 11(9):1167-80. PubMed ID: 15853664
[TBL] [Abstract][Full Text] [Related]
3. [Advances in the study of small peptides in targeted drug delivery system].
Sun Y; Wang C
Yao Xue Xue Bao; 2008 Oct; 43(10):992-6. PubMed ID: 19127861
[TBL] [Abstract][Full Text] [Related]
4. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
Schally AV; Nagy A
Eur J Endocrinol; 1999 Jul; 141(1):1-14. PubMed ID: 10407215
[TBL] [Abstract][Full Text] [Related]
5. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
6. Octreotide-Mediated Tumor-Targeted Drug Delivery via a Cleavable Doxorubicin-Peptide Conjugate.
Lelle M; Kaloyanova S; Freidel C; Theodoropoulou M; Musheev M; Niehrs C; Stalla G; Peneva K
Mol Pharm; 2015 Dec; 12(12):4290-300. PubMed ID: 26524088
[TBL] [Abstract][Full Text] [Related]
7. Peptide chemistry encounters nanomedicine: recent applications and upcoming scenarios in cancer.
Falanga A; Galdiero S
Future Med Chem; 2018 Aug; 10(16):1877-1880. PubMed ID: 29921135
[No Abstract] [Full Text] [Related]
8. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
9. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
10. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
Arosio D; Manzoni L; Corno C; Perego P
Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
[TBL] [Abstract][Full Text] [Related]
11. LHRH-Targeted Drug Delivery Systems for Cancer Therapy.
Li X; Taratula O; Taratula O; Schumann C; Minko T
Mini Rev Med Chem; 2017; 17(3):258-267. PubMed ID: 27739358
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptide.
Taheri A; Dinarvand R; Atyabi F; Ahadi F; Nouri FS; Ghahremani MH; Ostad SN; Borougeni AT; Mansoori P
Int J Mol Sci; 2011; 12(7):4591-608. PubMed ID: 21845098
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes.
Smith CJ; Volkert WA; Hoffman TJ
Nucl Med Biol; 2005 Oct; 32(7):733-40. PubMed ID: 16243649
[TBL] [Abstract][Full Text] [Related]
14. Targeting luteinizing hormone-releasing hormone: A potential therapeutics to treat gynecological and other cancers.
Ghanghoria R; Kesharwani P; Tekade RK; Jain NK
J Control Release; 2018 Jan; 269():277-301. PubMed ID: 27840168
[TBL] [Abstract][Full Text] [Related]
15. Design and Development of Polysaccharide-Doxorubicin-Peptide Bioconjugates for Dual Synergistic Effects of Integrin-Targeted and Cell-Penetrating Peptides for Cancer Chemotherapy.
Mansur AAP; Carvalho SM; Lobato ZIP; Leite MF; Cunha ADS; Mansur HS
Bioconjug Chem; 2018 Jun; 29(6):1973-2000. PubMed ID: 29790738
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides.
Dissanayake S; Denny WA; Gamage S; Sarojini V
J Control Release; 2017 Mar; 250():62-76. PubMed ID: 28167286
[TBL] [Abstract][Full Text] [Related]
17. Targeted Tubulysin B Hydrazide Conjugate for the Treatment of Luteinizing Hormone-Releasing Hormone Receptor-Positive Cancers.
Roy J; Kaake M; Srinivasarao M; Low PS
Bioconjug Chem; 2018 Jul; 29(7):2208-2214. PubMed ID: 29851465
[TBL] [Abstract][Full Text] [Related]
18. Function and molecular mechanism of tumor-targeted peptides for delivering therapeutic genes and chemical drugs.
Craig R; Li S
Mini Rev Med Chem; 2006 Jul; 6(7):757-64. PubMed ID: 16842125
[TBL] [Abstract][Full Text] [Related]
19. Seek & Destroy, use of targeting peptides for cancer detection and drug delivery.
Le Joncour V; Laakkonen P
Bioorg Med Chem; 2018 Jun; 26(10):2797-2806. PubMed ID: 28893601
[TBL] [Abstract][Full Text] [Related]
20. Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs.
Accardo A; Aloj L; Aurilio M; Morelli G; Tesauro D
Int J Nanomedicine; 2014; 9():1537-57. PubMed ID: 24741304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
